BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee JW, Choi JJ, Seo ES, Kim MJ, Kim WY, Choi CH, Kim TJ, Kim BG, Song SY, Bae DS. Increased toll-like receptor 9 expression in cervical neoplasia. Mol Carcinog. 2007;46:941-947. [PMID: 17440926 DOI: 10.1002/mc.20325] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 DeCarlo CA, Rosa B, Jackson R, Niccoli S, Escott NG, Zehbe I. Toll-like receptor transcriptome in the HPV-positive cervical cancer microenvironment. Clin Dev Immunol 2012;2012:785825. [PMID: 22013487 DOI: 10.1155/2012/785825] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
2 Rezania S, Amirmozaffari N, Rashidi N, Mirzadegan E, Zarei S, Ghasemi J, Zarei O, Katouzian L, Zarnani AH. The same and not the same: heterogeneous functional activation of prostate tumor cells by TLR ligation. Cancer Cell Int 2014;14:54. [PMID: 24966802 DOI: 10.1186/1475-2867-14-54] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
3 Martínez-campos C, Burguete-garcía AI, Madrid-marina V. Role of TLR9 in Oncogenic Virus-Produced Cancer. Viral Immunology 2017;30:98-105. [DOI: 10.1089/vim.2016.0103] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
4 Angrini M, Varthaman A, Cremer I. Toll-Like Receptors (TLRs) in the Tumor Microenvironment (TME): A Dragon-Like Weapon in a Non-fantasy Game of Thrones. In: Birbrair A, editor. Tumor Microenvironment. Cham: Springer International Publishing; 2020. pp. 145-73. [DOI: 10.1007/978-3-030-44518-8_9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Jain A, Kaczanowska S, Davila E. IL-1 Receptor-Associated Kinase Signaling and Its Role in Inflammation, Cancer Progression, and Therapy Resistance. Front Immunol 2014;5:553. [PMID: 25452754 DOI: 10.3389/fimmu.2014.00553] [Cited by in Crossref: 66] [Cited by in F6Publishing: 69] [Article Influence: 8.3] [Reference Citation Analysis]
6 Park JH, Yoon HE, Jeon DI, Ahn SG, Yoon JH. Activation of TLR2 and TLR5 did not affect tumor progression of an oral squamous cell carcinoma, YD-10B cells. J Oral Pathol Med 2010;39:781-5. [PMID: 20456615 DOI: 10.1111/j.1600-0714.2010.00900.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
7 Hsiao CC, Kao YH, Huang SC, Chuang JH. Toll-like receptor-4 agonist inhibits motility and invasion of hepatoblastoma HepG2 cells in vitro. Pediatr Blood Cancer 2013;60:248-53. [PMID: 22648929 DOI: 10.1002/pbc.24211] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
8 Zhou M, Mcfarland-mancini MM, Funk HM, Husseinzadeh N, Mounajjed T, Drew AF. Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunol Immunother 2009;58:1375-85. [DOI: 10.1007/s00262-008-0650-y] [Cited by in Crossref: 98] [Cited by in F6Publishing: 95] [Article Influence: 7.5] [Reference Citation Analysis]
9 Chang ZL. Important aspects of Toll-like receptors, ligands and their signaling pathways. Inflamm Res. 2010;59:791-808. [PMID: 20593217 DOI: 10.1007/s00011-010-0208-2] [Cited by in Crossref: 141] [Cited by in F6Publishing: 139] [Article Influence: 11.8] [Reference Citation Analysis]
10 Zhu J, Mohan C. Toll-like receptor signaling pathways--therapeutic opportunities. Mediators Inflamm 2010;2010:781235. [PMID: 20981241 DOI: 10.1155/2010/781235] [Cited by in Crossref: 83] [Cited by in F6Publishing: 104] [Article Influence: 6.9] [Reference Citation Analysis]
11 Lin A, Wang G, Zhao H, Zhang Y, Han Q, Zhang C, Tian Z, Zhang J. TLR4 signaling promotes a COX-2/PGE2/STAT3 positive feedback loop in hepatocellular carcinoma (HCC) cells. Oncoimmunology. 2015;5:e1074376. [PMID: 27057441 DOI: 10.1080/2162402x.2015.1074376] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
12 So EY, Ouchi T. The application of Toll like receptors for cancer therapy. Int J Biol Sci 2010;6:675-81. [PMID: 21060729 DOI: 10.7150/ijbs.6.675] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 6.3] [Reference Citation Analysis]
13 Yang X, Cheng Y, Li C. The role of TLRs in cervical cancer with HPV infection: a review. Signal Transduct Target Ther 2017;2:17055. [PMID: 29263932 DOI: 10.1038/sigtrans.2017.55] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
14 Martínez-Campos C, Bahena-Román M, Torres-Poveda K, Burguete-García AI, Madrid-Marina V. TLR9 gene polymorphism -1486T/C (rs187084) is associated with uterine cervical neoplasm in Mexican female population. J Cancer Res Clin Oncol 2017;143:2437-45. [PMID: 28819773 DOI: 10.1007/s00432-017-2495-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
15 Lee JY, Zhao L, Hwang DH. Modulation of pattern recognition receptor-mediated inflammation and risk of chronic diseases by dietary fatty acids. Nutr Rev 2010;68:38-61. [PMID: 20041999 DOI: 10.1111/j.1753-4887.2009.00259.x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 90] [Article Influence: 8.1] [Reference Citation Analysis]
16 Gatti G, Quintar AA, Andreani V, Nicola JP, Maldonado CA, Masini-Repiso AM, Rivero VE, Maccioni M. Expression of Toll-like receptor 4 in the prostate gland and its association with the severity of prostate cancer. Prostate 2009;69:1387-97. [PMID: 19496069 DOI: 10.1002/pros.20984] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 3.2] [Reference Citation Analysis]
17 Wang C, Cao S, Yan Y, Ying Q, Jiang T, Xu K, Wu A. TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients. BMC Cancer 2010;10:415. [PMID: 20696081 DOI: 10.1186/1471-2407-10-415] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
18 Laredj LN, Beard P. Adeno-associated virus activates an innate immune response in normal human cells but not in osteosarcoma cells. J Virol 2011;85:13133-43. [PMID: 21957288 DOI: 10.1128/JVI.05407-11] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
19 Bhat P, Mattarollo SR, Gosmann C, Frazer IH, Leggatt GR. Regulation of immune responses to HPV infection and during HPV-directed immunotherapy. Immunol Rev. 2011;239:85-98. [PMID: 21198666 DOI: 10.1111/j.1600-065x.2010.00966.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
20 Zhou Q, Zhu K, Cheng H. Toll-like receptors in human papillomavirus infection. Arch Immunol Ther Exp (Warsz) 2013;61:203-15. [PMID: 23435874 DOI: 10.1007/s00005-013-0220-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
21 Gutierrez-Xicotencatl L, Salazar-Piña DA, Pedroza-Saavedra A, Chihu-Amparan L, Rodriguez-Ocampo AN, Maldonado-Gama M, Esquivel-Guadarrama FR. Humoral Immune Response Against Human Papillomavirus as Source of Biomarkers for the Prediction and Detection of Cervical Cancer. Viral Immunol 2016;29:83-94. [PMID: 26780189 DOI: 10.1089/vim.2015.0087] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
22 Hamdy S, Osman AM, Zakaria ZA, Galal I, Sobhy M, Hashem M, Allam WR, Abdel-samiee M, Rewisha E, Waked I, Abdelwahab SF. Association of Toll-like receptor 3 and Toll-like receptor 9 single-nucleotide polymorphisms with hepatitis C virus persistence among Egyptians. Arch Virol 2018;163:2433-42. [DOI: 10.1007/s00705-018-3893-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
23 Basith S, Manavalan B, Yoo TH, Kim SG, Choi S. Roles of toll-like receptors in cancer: a double-edged sword for defense and offense. Arch Pharm Res. 2012;35:1297-1316. [PMID: 22941474 DOI: 10.1007/s12272-012-0802-7] [Cited by in Crossref: 117] [Cited by in F6Publishing: 114] [Article Influence: 11.7] [Reference Citation Analysis]
24 Sen S, Mandal P, Bhattacharya A, Kundu S, Roy Chowdhury R, Mondal NR, Chatterjee T, Chakravarty B, Roy S, Sengupta S. Impact of viral and host DNA methylations on HPV16-related cervical cancer pathogenesis. Tumour Biol 2017;39:101042831769979. [DOI: 10.1177/1010428317699799] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
25 Pandey S, Mittal B, Srivastava M, Singh S, Srivastava K, Lal P, Mittal RD. Evaluation of Toll-like receptors 3 (c.1377C/T) and 9 (G2848A) gene polymorphisms in cervical cancer susceptibility. Mol Biol Rep. 2011;38:4715-4721. [PMID: 21132533 DOI: 10.1007/s11033-010-0607-z] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 4.9] [Reference Citation Analysis]
26 Kutikhin AG, Yuzhalin AE. The Biology of Toll-Like Receptors and NOD-Like Receptors: The Toggles of Inflammation. Genomics of Pattern Recognition Receptors. Basel: Springer; 2013. pp. 1-25. [DOI: 10.1007/978-3-0348-0688-6_1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
27 Min R, Zun Z, Siyi L, Wenjun Y, Lizheng W, Chenping Z. Increased expression of Toll-like receptor-9 has close relation with tumour cell proliferation in oral squamous cell carcinoma. Arch Oral Biol 2011;56:877-84. [PMID: 21333270 DOI: 10.1016/j.archoralbio.2011.01.010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
28 Sonnex C. Toll-like receptors and genital tract infection. Int J STD AIDS 2010;21:153-7. [PMID: 20215617 DOI: 10.1258/ijsa.2009.009525] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
29 Khan A, Khan Z, Warnakulasuriya S. Cancer-associated toll-like receptor modulation and insinuation in infection susceptibility: association or coincidence? Annals of Oncology 2016;27:984-97. [DOI: 10.1093/annonc/mdw053] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
30 Sobstyl M, Niedźwiedzka-Rystwej P, Hrynkiewicz R, Bębnowska D, Korona-Głowniak I, Pasiarski M, Sosnowska-Pasiarska B, Smok-Kalwat J, Góźdź S, Sobstyl A, Polkowski W, Roliński J, Grywalska E. Toll-like Receptor 2 as a Marker Molecule of Advanced Ovarian Cancer. Biomolecules 2021;11:1205. [PMID: 34439871 DOI: 10.3390/biom11081205] [Reference Citation Analysis]
31 Muehleisen B, Jiang SB, Gladsjo JA, Gerber M, Hata T, Gallo RL. Distinct innate immune gene expression profiles in non-melanoma skin cancer of immunocompetent and immunosuppressed patients. PLoS One 2012;7:e40754. [PMID: 22808251 DOI: 10.1371/journal.pone.0040754] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
32 Hsiao C, Chen P, Cheng C, Tsai M, Chang C, Lu S, Hsieh M, Lin Y, Lee P, Kao Y. Toll-like receptor-4 is a target for suppression of proliferation and chemoresistance in HepG2 hepatoblastoma cells. Cancer Letters 2015;368:144-52. [DOI: 10.1016/j.canlet.2015.08.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
33 Melisi D, Frizziero M, Tamburrino A, Zanotto M, Carbone C, Piro G, Tortora G. Toll-Like Receptor 9 Agonists for Cancer Therapy. Biomedicines 2014;2:211-28. [PMID: 28548068 DOI: 10.3390/biomedicines2030211] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
34 Choi CH, Chung JY, Park HS, Jun M, Lee YY, Kim BG, Hewitt SM. Pancreatic adenocarcinoma up-regulated factor expression is associated with disease-specific survival in cervical cancer patients. Hum Pathol 2015;46:884-93. [PMID: 25870121 DOI: 10.1016/j.humpath.2015.02.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
35 Oliveira LB, Louvanto K, Ramanakumar AV, Franco EL, Villa LL, For The Ludwig-McGill Cohort Study. Polymorphism in the promoter region of the Toll-like receptor 9 gene and cervical human papillomavirus infection. J Gen Virol 2013;94:1858-64. [PMID: 23677790 DOI: 10.1099/vir.0.052811-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
36 Yang S, Liu L, Xu D, Li X. The Relationship of the TLR9 and TLR2 Genetic Polymorphisms with Cervical Cancer Risk: a Meta-Analysis of Case-Control Studies. Pathol Oncol Res 2020;26:307-15. [PMID: 30215163 DOI: 10.1007/s12253-018-0465-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
37 Atkinson TJ. Toll-like receptors, transduction-effector pathways, and disease diversity: evidence of an immunobiological paradigm explaining all human illness? Int Rev Immunol 2008;27:255-81. [PMID: 18574739 DOI: 10.1080/08830180801959072] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
38 Yu L, Wang L, Chen S. REVIEW ARTICLE: Toll-Like Receptors, Inflammation and Tumor in the Human Female Reproductive Tract: TLRS IN FEMALE REPRODUCTIVE TRACT. American Journal of Reproductive Immunology 2009;62:1-8. [DOI: 10.1111/j.1600-0897.2009.00712.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
39 Sato Y, Goto Y, Narita N, Hoon DS. Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment. Cancer Microenviron. 2009;2 Suppl 1:205-214. [PMID: 19685283 DOI: 10.1007/s12307-009-0022-y] [Cited by in Crossref: 182] [Cited by in F6Publishing: 181] [Article Influence: 14.0] [Reference Citation Analysis]
40 Cannella F, Pierangeli A, Scagnolari C, Cacciotti G, Tranquilli G, Stentella P, Recine N, Antonelli G. TLR9 is expressed in human papillomavirus-positive cervical cells and is overexpressed in persistent infections. Immunobiology 2015;220:363-8. [PMID: 25454809 DOI: 10.1016/j.imbio.2014.10.012] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
41 Meneghin A, Choi ES, Evanoff HL, Kunkel SL, Martinez FJ, Flaherty KR, Toews GB, Hogaboam CM. TLR9 is expressed in idiopathic interstitial pneumonia and its activation promotes in vitro myofibroblast differentiation. Histochem Cell Biol 2008;130:979-92. [PMID: 18633634 DOI: 10.1007/s00418-008-0466-z] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
42 Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 2008;27:218-24. [PMID: 18176603 DOI: 10.1038/sj.onc.1210904] [Cited by in Crossref: 233] [Cited by in F6Publishing: 233] [Article Influence: 16.6] [Reference Citation Analysis]
43 Yu L, Wang L, Li M, Zhong J, Wang Z, Chen S. Expression of toll-like receptor 4 is down-regulated during progression of cervical neoplasia. Cancer Immunol Immunother 2010;59:1021-8. [PMID: 20177675 DOI: 10.1007/s00262-010-0825-1] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 4.3] [Reference Citation Analysis]
44 Yu L, Chen S. Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother. 2008;57:1271-1278. [PMID: 18256828 DOI: 10.1007/s00262-008-0459-8] [Cited by in Crossref: 81] [Cited by in F6Publishing: 82] [Article Influence: 5.8] [Reference Citation Analysis]
45 Kauppila JH, Karttunen TJ, Saarnio J, Nyberg P, Salo T, Graves DE, Lehenkari PP, Selander KS. Short DNA sequences and bacterial DNA induce esophageal, gastric, and colorectal cancer cell invasion. APMIS 2013;121:511-22. [PMID: 23082743 DOI: 10.1111/apm.12016] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
46 Ohadian Moghadam S, Nowroozi MR. Toll‐like receptors: The role in bladder cancer development, progression and immunotherapy. Scand J Immunol 2019;90. [DOI: 10.1111/sji.12818] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
47 Mohamed FE, Al-Jehani RM, Minogue SS, Andreola F, Winstanley A, Olde Damink SW, Habtesion A, Malagó M, Davies N, Luong TV. Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver Int. 2015;35:1063-1076. [PMID: 24990399 DOI: 10.1111/liv.12626] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
48 Zhou C, Tuong ZK, Frazer IH. Papillomavirus Immune Evasion Strategies Target the Infected Cell and the Local Immune System. Front Oncol 2019;9:682. [PMID: 31428574 DOI: 10.3389/fonc.2019.00682] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 13.7] [Reference Citation Analysis]
49 Gowing SD, Cool-Lartigue JJ, Spicer JD, Seely AJE, Ferri LE. Toll-like receptors: exploring their potential connection with post-operative infectious complications and cancer recurrence. Clin Exp Metastasis 2020;37:225-39. [PMID: 31975313 DOI: 10.1007/s10585-020-10018-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
50 Hasimu A, Ge L, Li QZ, Zhang RP, Guo X. Expressions of Toll-like receptors 3, 4, 7, and 9 in cervical lesions and their correlation with HPV16 infection in Uighur women. Chin J Cancer 2011;30:344-50. [PMID: 21527067 DOI: 10.5732/cjc.010.10456] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
51 Sheyhidin I, Nabi G, Hasim A, Zhang RP, Ainiwaer J, Ma H, Wang H. Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J Gastroenterol 2011; 17(32): 3745-3751 [PMID: 21990957 DOI: 10.3748/wjg.v17.i32.3745] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 64] [Article Influence: 6.2] [Reference Citation Analysis]
52 Kutikhin AG. Association of polymorphisms in TLR genes and in genes of the Toll-like receptor signaling pathway with cancer risk. Hum Immunol. 2011;72:1095-1116. [PMID: 21872627 DOI: 10.1016/j.humimm.2011.07.307] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 6.5] [Reference Citation Analysis]
53 Takala H, Kauppila JH, Soini Y, Selander KS, Vuopala KS, Lehenkari PP, Saarnio J, Karttunen TJ. Toll-like receptor 9 is a novel biomarker for esophageal squamous cell dysplasia and squamous cell carcinoma progression. J Innate Immun 2011;3:631-8. [PMID: 21876325 DOI: 10.1159/000329115] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
54 Tarang S, Kumar S, Batra SK. Mucins and toll-like receptors: kith and kin in infection and cancer. Cancer Lett 2012;321:110-9. [PMID: 22306702 DOI: 10.1016/j.canlet.2012.01.040] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
55 Husseinzadeh N, Davenport SM. Role of Toll-like receptors in cervical, endometrial and ovarian cancers: A review. Gynecologic Oncology 2014;135:359-63. [DOI: 10.1016/j.ygyno.2014.08.013] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
56 Weng Y, Wang Y, Shi Y, Zhou W, Wang H, Wang C. TLR9 expression and its role in chemosensitivity to DDP in human cervical cancer cells in vitro. J Huazhong Univ Sci Technolog Med Sci 2011;31:550. [PMID: 21823020 DOI: 10.1007/s11596-011-0488-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
57 Aggarwal R, Misra S, Guleria C, Suri V, Mangat N, Sharma M, Nijhawan R, Minz R. Characterization of Toll-like receptor transcriptome in squamous cell carcinoma of cervix: A case-control study. Gynecol Oncol 2015;138:358-62. [PMID: 26024767 DOI: 10.1016/j.ygyno.2015.05.029] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
58 Moura ELD, Santos IFD, Freitas PPD, Silva DMD, Santos ACMD, Lira Neto AB, Silva ACPE, Barbosa NR, Nascimento CA, Balliano TL, Fraga CADC, Farias KFD, Figueiredo EVMDS. Polymorphisms in Toll-like receptors genes changes the host’s immune response and is associated with cervical cancer. Immunobiology 2022;227:152187. [DOI: 10.1016/j.imbio.2022.152187] [Reference Citation Analysis]